Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis
Hernández-Boluda, Juan Carlos; Pereira, Arturo; Correa, Juan-Gonzalo; Álvarez-Larrán, Alberto; Ferrer-Marín, Francisca; Raya, José-María; Martínez López, Joaquín; Pérez Encinas, Manuel Mateo; Estrada, Natalia; Velez, Patricia; Fox, María-Laura; García-Gutiérrez, Valentín; Payer, Ángel; Kerguelen, Ana; Cuevas, Beatriz; Durán, María-Antonia; Ramírez, María-José; Gómez-Casares, María-Teresa; Mata-Vázquez, María-Isabel; Mora, Elvira; Martínez-Valverde, C.; Gómez, Montse; Cervantes, Francisco
Identificadores
Identificadores
URI: http://hdl.handle.net/20.500.11940/22446
PMID: 28935991
DOI: 10.1038/leu.2017.297
ESSN: 1476-5551
Visualización ou descarga de ficheiros
Visualización ou descarga de ficheiros
Data de publicación
2018Título da revista
Leukemia
Tipo de contido
Artigo
DeCS
pronóstico | mielofibrosis primaria | sistema de registros | policitemia vera | trombocitemia esencialMeSH
Prognosis | Thrombocythemia, Essential | Primary Myelofibrosis | Polycythemia Vera | RegistriesCIE
Enfermedad mieloproliferativa crónicaResumo
[EN] Recently, Passamonti et al have developed a new prognostic model to specifically address the prediction of survival in patients with secondary MF, the Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSECPM). It is worth noting that this prognostic model has not yet been tested in an independent series of patients. The objective was to investigate the performance of the MYSEC-PM, as compared with the International Prognostic Scoring System (IPSS), in a nationwide series of 262 patients with secondary MF from the Spanish Registry of Myelofibrosis. In conclusion, the present study confirms that MYSEC-PM allows a more accurate prediction of survival than IPSS in patients with secondary MF. However, clinicians must be aware of some relevant issues.

Ítems relacionados
Mostrando rexistros relacionados por Título, autor ou palabra clave.










